C9orf72 and Parkinson disease: C9orf72 HRE carriers showed significantly different parkinsonism incidence compared to controls by log rank testing (P = 0.034), but no higher cumulative incidence by age 80 [4.3% (0.8%–7.7%) versus 2.4% (1.5%–3.2%); Supplementary Fig. 2].